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Background: Tumors with a massive inflammatory infiltration are described in several organs. There is
agreement about considering the inflammatory infiltration as the host’s immune response to neoplastic cells;
such neoplasms indeed have a better prognostic outcome than non-inflammatory counterparts. Only
seventeen cases of pulmonary adenocarcinoma with massive lymphocytic infiltration (AMLI) have been
reported in literature so far.
Case presentation: We present a case of pulmonary adenocarcinoma with massive lymphocytic infiltration
occurring in a 71 years old male smoker. He came under our attention because of dyspnea, and underwent a
left lower lobectomy. Histological examination showed a moderately differentiated (G2) acinar
adenocarcinoma associated with a stromal desmoplastic reaction and a massive inflammatory infiltration,
made up mostly of CD3+ lymphocytes. pTNM stage was pT2a, N0 (clinical stage: Ib).
Molecular testing of EGFR gene showed no mutations and immunohistochemistry for ALK resulted negative.
EBV infection was ruled out by EBV in situ hybridization.
Conclusions: Literature review showed seventeen similar cases, with a 16/1 male/female ratio and a mean
age of 70,2 years. In eight out of seventeen cases EBV-infection was demonstrated with immunohistochemical
or molecular biology techniques.
Similarly to the cases previously reported in literature our patient is a male smoker, without lymph node
metastasis and he is still alive after a follow-up period of six months without recurrent or residual disease.
Because of histological, biological and clinical peculiarity, we propose to take into account pulmonary
adenocarcinomas with massive inflammatory infiltration for a separate pathological classification.
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Tumors with a massive inflammatory infiltration are found
in different sites such as gastrointestinal tract, liver, breast
and female genital system [1-6].
The inflammatory infiltrate, which is thought to depict
the immune response to neoplastic cells, has been stud-
ied mainly in large bowel cancer, and is linked to an im-
proved prognostic outcome. It is typically mixed and
made up of lymphocytes, macrophages, dendritic cells and
granulocytes [7].
Lung pathology displays a well-defined tumor entity
with massive lymphoid infiltration, lymphoepithelioma-like
carcinoma (LELC). It is a subtype of large cell carcinoma
often related, especially in Asiatic patients, to Epstein-Barr
Virus (EBV) infection.
This entity shares most pathological features with the
nasopharingeal counterpart [8].
Pulmonary adenocarcinoma with massive lymphocytic
infiltration (AMLI) is not included as a separate entity in
current World Health Organization (WHO) classifica-
tion of tumors or in the new multidisciplinary patho-
logical classification published in 2011 by Travis et al.
[9]; though, it is recognized by some sources as a rare
histological variant of pulmonary adenocarcinoma [10].
To the best of our knowledge, only seventeen cases of
AMLI are reported in literature so far.
AMLI is distinguished from ''classic'' acinar adenocar-
cinoma by the tendency to occur in advanced-age males;
prognosis is way better since the massive flogistic infil-
trate reflects the active host's immune response. More-
over, cytological diagnosis may be misleading, because of
the relative paucity of neoplastic cells and the wide pre-
dominance of inflammatory subsets [11].
Glandular acinar differentiation was found in all cases;
a marked fibrous stroma was a common finding too.
Typically, inflammatory cells are more represented and
tend to overwhelm the neoplastic counterpart, with dif-
fuse infiltration and effacement of tumoral glands. This,
as said before, leads to a relative paucity of neoplastic
cells [12,13].
In nine cases [11,12], EBV infection was ruled out by
immunohistochemical or molecular biology techniques,
and in the other eight cases reported in literature [14]
EBV positivity was demonstrated in neoplastic tissue.
Further immunophenotypical characterization of the
infiltrate showed a prevalent T-lymphoid distribution,
with a greater extent of CD8+ cells. B-cells, plasma cells,
macrophages and granulocytes were represented at a
lower amount; prominent reactive germinal centers were
found in a minority of cases [12,13].
We report a case of a 71 years old man who underwent
a lower left lobectomy, with a postoperative histopatho-
logical diagnosis of pulmonary acinar adenocarcinoma with
massive lymphocytic infiltration.Case presentation
A 71 years old male came to our attention because of
dyspnea during the last three months.
A chest computed tomography scan showed a 35 ×
25 mm central pulmonary nodule of the lower left lobe
with no evidence of thoracic lymphoadenopaties.
A positron emission tomography (PET) scan demon-
strated the concentration of fluorodeoxyglucose (FDG) in
that nodule, with a peripheral rim of hyperfixation (stand-
ard uptake value max 6.9).
The patient underwent a left lower lobectomy with
omolateral mediastinal lymphoadenectomy; gross examin-
ation of the specimen showed a 3.8 cm greyish nodule, with
stellate margins and no involvement of the visceral pleura.
Light microscopy showed a moderately-differentiated
(G2) acinar adenocarcinoma, with marked stromal fibro-
sis. Necrosis was not found (Figure 1A).
A massive lymphocytic reaction, with a diffuse pattern of
growth and several aspects of infiltration of neoplastic
glands was present in the tumoral stroma. No germinal
centers were highlighted. Immunohistochemistry revealed
a strong positivity of the tumoral cells for TTF-1 (DAKO,
clone 86763/1) and Napsin-A (DAKO, policlonal) anti-
bodies, confirming the glandular histogenesis and the pul-
monary primitivity (Figure 1B).
The lymphoid component was found to be policlonal
and made up mainly by CD3+ (DAKO, clone 2GV6,
Rabbit) T-cells. Cytotoxic (CD8+, DAKO, clone C8/144B)
T-lymphocytes were more represented than helper (CD4+,
DAKO, clone 5835) cells (Figure 1C and 1D). EBV infec-
tion was excluded by an EBV Encoded Small RNAs (EBER)
probe negative in situ hybridization.
According to these histological findings, we made a
diagnosis of pulmonary adenocarcinoma with massive
lymphocytic infiltration.
All the mediastinal lymphnodes showed antracosis and
sinus hystiocitosis without evidence of metastasis.
Molecular testing of the EGFR gene (regions investi-
gated: exon 18 codon 719, exon 19 codon 746–750, exon
21 codons 858 and 861) performed by pyrosequencing,
using the "Pyromark Q96 ID System" with the diagnostic
kit IVD / CE EGFR TKI response (Diatech Pharmacogen-
etics srl) showed no mutations.
Molecular testing of the KRAS gene (regions investigated:
codon 12, 13, 61 and 146) performed by pyrosequencing
using the "Pyromark Q96 ID System" with the diagnostic
kit IVD / CE Anti-EGFR mAb response (KRAS status)
[Diatech Pharmacogenetics Srl] showed a wild type
phenotype.
Lastly, immunostaining for ALK (Novocastra, clone
5A4) resulted negative.
After a follow up period of six months, the patient is
in good health with no evidence of residual or recur-
rent disease.
Figure 1 Histological and immunoistochemical features of the case. A: Neoplastic glands surrounded and infiltrated by a massive
inflammatory infiltration (H&E, 10×); B: Immunoreactivity for Napsin-A confirms the glandular nature of the tumor (10×); C,D: The infiltrate was
composed predominantly of CD8+ lymphocytes (C, 10×) and CD4+ lymphocytes (D, 10×).
Table 1 Cases of pulmonary adenocarcinomas with massive
lymphocytic infiltration reported in literature
Case N. Age Sex Smoke Stage Follow-up
(mths)
EBV
infection
1 68 M n.a. IIIb Alive (62) Negative
2 75 M n.a. IIIa Dead (26) Negative
3* 64 M n.a. Ia Alive (98) Negative
4 70 F + IIIa Alive (98) Negative
5 55 M + IIIa Alive (67) Negative
6 85 M + n.a. Alive (57) Negative
7 72 M + IIa Alive (48) Negative
8 68 M + Ia Alive (17) Negative
9** 75 M + IIIa Alive (12) Negative
10 72 M n.a. Ib Dead (26) Positive
11 61 M n.a. Ia Alive (40) Positive
12 54 M n.a. Ia Lost follow-up Positive
13 70 M n.a. Ib Lost follow-up Positive
14 69 M n.a. Ib Lost follow-up Positive
15 55 M n.a. IIIa Dead (1) Positive
16 67 M n.a. IIIa Alive (12) Positive
17*** 58 M n.a. Ia Alive (36) Positive
18**** 71 M + Ib Alive (6) Negative
(*Case 1 through 3: Minami Y et al., Lung Cancer, 2003; **Case 4 through 9:
Tsuta K et al., Am J Clin Path, 2005; ***Case 10 through 17: Gomez-Roman et al.,
Modern Pathology, 2009; ****Case 18: current report).
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An inflammatory response of a variable degree, interpreted
as the host's attempt to contain neoplastic growth, is de-
tectable in most tumors [7]. Though, a relevant inflamma-
tory infiltration can be found only in small percentages of
tumors.
The current (2004) WHO classification of tumors of
the Lung, Pleura, Thymus and Heart contains an only
entity associated with intratumoral inflammatory infil-
trate: lymphoepithelioma-like carcinoma, which is classi-
fied as a histological variant of large cell carcinoma. This
neoplasm is overall rare but accounts for around 1% of
all the lung tumors in China.
It is made up by poorly differentiated epithelial cells with
a prominent lymphoid stroma, and is strictly associated
with EBV infection, detectable in nearly 100% of cases [8].
In our case, the neoplastic component is represented
by acinar glands, with a smaller account of solid areas.
In support of the glandular nature of this neoplasm
there is immunohistochemical positivity for Napsin-A
and TTF-1 antibodies.
Literature displays, after an extensive search, only three
other studies concerning adenocarcinoma with massive
lymphocytic infiltration (AMLI).
Minami et al. described three cases of AMLI. All data,
apart from the prevalent CD4+ phenotype of stromal
lymphocytes, overlap our findings [12].
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port, the prevalent lymphocyte phenotype was CD8+.
All nine cases showed a diffuse pattern of growth of the
lymphoid infiltrate, with only few germinal centers and a
smaller amount of peripheral distributed B-cells [13]. In
these cases, EBV infection was ruled out.
Gomez-Roman et al. reported eight cases of lung
adenocarcinoma with a diffuse lymphoid stroma and
a tubuloglandular pattern, associated with EBV infec-
tion [14].
The most relevant findings of these three papers are
reported in Table 1.
In our opinion, the main data to focus on is that
AMLI more frequently occurs in advanced-age male
with a significant better prognostic outcome than classic
acinar adenocarcinoma despite the presence of lymph
node metastases.
In our case, the tumor is characterized by the typical
molecular profile of lung carcinomas arising in smokers,
with EGFR and ALK wild type phenotype [15,16].
Although lacking a molecular target for targeted ther-
apy and expecting a poor outcome, these tumors have a
good prognosis, due to their biology and to the host im-
mune defense.
Peculiar histological, molecular and clinical features
may suggest a distinct classification of the tumor. Unfor-
tunately, prevailing data are not adequate to assess real
incidence of AMLI. It would be advantageous to furtherly
consider AMLI in future studies, in order to be able to
place it in a separate pathologic category.Consent
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